CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells 45,147 Shares

Key Points

• Director Andrew Schwab sold 45,147 CAMP shares at an average price of $4.76, totaling approximately $214,900. He retained 2.58 million shares after the transaction, a 1.72% reduction in ownership.
• CAMP shares rose 0.4% to $4.48 in mid-day trading, while the company reported quarterly revenue of $1.78 million and an EPS loss of $0.58, missing analyst estimates by $0.34.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $9.56; Piper Sandler recently raised its target to $15.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) Director Andrew Schwab sold 45,147 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $4.76, for a total value of $214,899.72. Following the completion of the sale, the director directly owned 2,579,998 shares of the company's stock, valued at approximately $12,280,790.48. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

CAMP4 Therapeutics Trading Up 0.4%

Shares of CAMP traded up $0.02 during mid-day trading on Friday, hitting $4.48. The company's stock had a trading volume of 126,663 shares, compared to its average volume of 183,971. CAMP4 Therapeutics Corporation has a 1-year low of $1.41 and a 1-year high of $7.75. The firm has a market capitalization of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22. The firm has a 50-day simple moving average of $4.11 and a 200 day simple moving average of $4.33.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The company had revenue of $1.78 million during the quarter. As a group, sell-side analysts predict that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current fiscal year.

Analyst Ratings Changes

CAMP has been the topic of a number of recent research reports. Piper Sandler restated an "overweight" rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Zacks Research raised shares of CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 10th. Finally, Weiss Ratings upgraded shares of CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.56.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently bought and sold shares of CAMP. Bridgeway Capital Management LLC acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in CAMP4 Therapeutics during the 4th quarter worth about $61,000. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at approximately $70,000. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics in the second quarter worth $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source